

Addendum

Addendum: Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)**Hazem I. Assi^{1,*}, Maroun Bou Zerdan^{1,*}, Mohammad Hodroj¹, Makram Khoury², Nour Sabiha Naji¹, Ghid Amhaz¹, Reine Abou Zeidane¹ and Fadi El Karak²**¹Department of Internal Medicine, Division of Hematology and Oncology, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon²Department of Internal Medicine, Division of Hematology and Oncology, Hotel Dieu de France University Hospital, Beirut, Lebanon

*These authors contributed equally to this work

Published:**Copyright:** © 2023 Assi et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.**This article has an addendum:** No funding was used for this publication.Original article: Oncotarget. 2023; 14:517–525. <https://doi.org/10.18632/oncotarget.28444>